Insider · CIK 0001985801
Qasim Iftikhar Ahmad
Files at IOBT (IO Biotech, Inc.). First filing Dec 26, 2024, latest Dec 26, 2024.
In brief
Qasim Iftikhar Ahmad files SEC Form 4 as officer at IOBT (IO Biotech, Inc.). Since Dec 26, 2024, Qasim Iftikhar Ahmad has reported 1 open-market buy worth $27k and 0 open-market sells worth $0, the latest filed on Dec 26, 2024.
A track record needs three past buys with six months of prices behind them; Qasim Iftikhar Ahmad has 0, so none is measured yet.
The newest scored trade: bought $27k of IOBT on Dec 23, 2024, filed Dec 26, 2024, scored 43 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | IO Biotech, Inc. | $27k 31,350 shares | - | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Apr 4, 2025 |
| Dec 23, 2024 | IOBT IO Biotech, Inc. | POpen-market purchase Common Stock | +31,350 | $0.85 | $27k | 31,350 | Dec 26, 2024 |
| Mar 15, 2024 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Mar 18, 2024 |
Questions about Qasim Iftikhar Ahmad
Answered from the filings on this page, as of the latest one.
Is Qasim Iftikhar Ahmad buying or selling?
Not in the last 12 months. Qasim Iftikhar Ahmad's latest open-market trade on SEC Form 4 was bought $27k of IOBT on Dec 23, 2024.
How did Qasim Iftikhar Ahmad's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Qasim Iftikhar Ahmad has 0.
Where does Qasim Iftikhar Ahmad file Form 4?
Qasim Iftikhar Ahmad has filed Form 4 at IOBT (IO Biotech, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.